GlassScriptPhysician profile
Richard Tucker
NPI 1376514448
$556.62
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $84.54 · 2021: $39.75 · 2022: $29.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $173.91 | 2019-2021 | |
| Amgen INC. | $84.00 | 2019-2021 | |
| Ethicon US, LLC | $79.08 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $55.13 | 2019 | |
| Therapeuticsmd, INC. | $42.78 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $28.53 | 2019-2020 | |
| Millicent US INC | $25.58 | 2019 | |
| Evofem Biosciences, INC. | $14.99 | 2022 | |
| Dysis Medical, INC. | $14.13 | 2022 | |
| Mayne Pharma Commercial LLC | $13.75 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.60 | 2019 | |
| Exeltis, USA INC. | $12.14 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.